Brief: Cingulate Inc Reports Q3 Loss Of $0.36 Per Share

Societal CDMO

14/11/2022 12:56

Nov 14 (Reuters) - Cingulate Inc  CING.O :
    * CINGULATE INC. REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS AND
PROVIDES CLINICAL AND BUSINESS UPDATE
    * CINGULATE INC - PHASE 3 TRIAL INITIATION FOR LEAD ADHD
CANDIDATE
CTX-1301 IN DECEMBER 2022
    * CINGULATE INC - QTRLY LOSS PER SHARE $0.36
    * CINGULATE INC - AS OF SEPTEMBER 30, 2022, CINGULATE HAD
$9.8
MILLION IN CASH AND CASH EQUIVALENTS
    * CINGULATE INC - UPON POSITIVE CLINICAL RESULTS FROM PHASE
3
TRIALS AND FOOD EFFECT STUDY, CO PLANS TO SUBMIT NDA FOR
CTX-1301 IN FIRST HALF OF 2024
    * CINGULATE INC - EVALUATING ALTERNATIVES TO RAISE
ADDITIONAL
CAPITAL, INCLUDING EQUITY AND DEBT FINANCING
    * CINGULATE INC - EXPECTS CASH AND CASH EQUIVALENTS TO
ENABLE TO
FUND RESEARCH & DEVELOPMENT & GENERAL & ADMINISTRATIVE
EXPENDITURES THROUGH Q1 OF 2023

Source text for Eikon:  ID:nGNX3Jf83Z 
Further company coverage:  CING.O 
 ((Reuters.Briefs@thomsonreuters.com;))